The Study
370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms
This study shows that when people with obesity and diabetes took this new medicine, they lost fat and gained muscle—even without eating less. But it doesn't prove the medicine caused it for sure, because we don't know if everyone was kept unaware of who got the real drug.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested a new medicine that tricks the body into burning fat and building muscle, even if you eat the same amount.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 570 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Losing over 20% of body fat and gaining muscle without dieting or exercise is a big deal — it could mean better health and longer-lasting weight loss than current drugs.
- 2Fat dropped by 22.2%, muscle went up by 3.6%, belly fat dropped by 36.1%, liver fat dropped by 23.6%, and blood sugar improved — all without eating less.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2023
Authors
K. Attie, S. Heymsfield, L. Mindeholm, S. Spruill, M. Pruzanski, Lloyd B Klickstein
Related Content
Claims (6)
Bimagrumab, a specific antibody, decreases body fat without requiring the presence or activity of GLP-1 receptor agonists.
In adults with obesity and type 2 diabetes, receiving bimagrumab via intravenous injection once a week for 48 weeks reduces body fat by 22.2% and increases lean mass by 3.6%, without changes in calorie intake, showing the drug directly alters body composition.
In adults with obesity and type 2 diabetes, bimagrumab lowers HbA1c by 0.76% over 48 weeks, while placebo causes a 0.04% increase, regardless of changes in calorie consumption.
When bimagrumab is injected under the skin instead of into a vein at a dose of 525 mg every four weeks for 12 weeks, it reduces fat mass and increases lean mass to the same degree as the intravenous route, while causing fewer side effects.
In adults with obesity and type 2 diabetes, bimagrumab reduces visceral fat by 36.1% and liver fat by 23.6% within 24 weeks, regardless of changes in calorie intake.
In adults with obesity and type 2 diabetes, fat mass lost during treatment with bimagrumab remains reduced for at least 12 weeks after stopping the drug.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.